[SAT-118] Restoring Testosterone to Normal Levels in Elderly Men Is Efficacious in Weight Reduction. A Follow-Up Study over 5 Years
Farid Saad, Ahmad Haider, Louis Gooren. Bayer Pharma AG, Berlin, Germany; Gulf Medical University School of Medicine, Ajman, United Arab Emirates; Private Practice, Bermerhaven, Germany; VUMC Amsterdam, Amsterdam, Netherlands.
Introduction: Obesity is associated with reduced testosterone, and low testosterone induces weight gain. This study analysed the effects of normalization of serum testosterone in mainly elderly, hypogonadal men.
Methods: Open-label, single-center, cumulative, prospective registry study of 255 men (aged 38 – 83 years, mean 60.6 ± 8.0 years), with testosterone levels between 1.7 –3.5 ng/mL (mean: 2.87 ± 0.4). Cut-off point for testosterone treatment was serum testosterone ≤ 3.5. ng/mL). 215 men were studied for at least 2 years, 182 for 3 years, 148 for 4 and 116 for at least 5 years. They received parenteral testosterone undecanoate 1000 mg/12 weeks after an initial interval of 6 weeks.
Results: After 5 years the following changes were observed: weight (kg) decreased from 106.22 ± 16.93 (minimum: 70, maximum: 139) to 90.07 ± 9.51 (min 74.00, max 115). The statistical significance was p<0.0001 vs baseline and vs the previous year over 5 years indicating a continuous weight loss over the full observation period. Waist circumference (cm) declined from 107.24 ± 9.14 (min 86, max 129) to 98.46 ± 7.39 (min 84, max 117) (p<0.0001 vs baseline and vs the previous year over 5 years). Body mass index (BMI, m/kg2) declined from 33.93 ± 5.54 (min 21.91, max 46.51) to 29.17 ± 3.09 (min 22.7; max 36.71) (p<0.0001 vs baseline and vs the previous year over 5 years). The mean per cent weight loss after 1 year was 4.12 ± 3.48%, after 2 years 7.47 ± 5.01%, after 3 years 9.01 ± 6.5%, after 4 years 11.26 ± 6.76% and after 5 years 13.21 ± 7.24%. At baseline, 96% of men had a waist circumference of ≥ 94 cm. This proportion decreased to 71% after 5 years.
Conclusions: Raising serum testosterone to normal produced loss of body weight, waist circumference and BMI. These improvements were progressive over the full 5 years of the study.
Sources of Research Support: Data entry and statistical analysis were supported by Bayer Pharma AG.
Disclosures: FS: Employee, Bayer Schering Pharma. AH: Principal Investigator, Bayer Schering Pharma. LG: Speaker, Bayer Schering Pharma.
Date: Saturday, June 23, 2012
Session Info: POSTER SESSION: Obesity Topics II (1:30 PM-3:30 PM)
Presentation Time: 1:30 pm
Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.
The information presented at ENDO news conferences and within the Research Summaries Book represents the opinion of the presenters and authors and is not necessarily the view of The Endocrine Society. The Endocrine Society makes no representation as to the truth or warranty, accuracy, or originality of the information presented.
For additional information, please contact The Endocrine Society’s Public Affairs Department at 240-482-1380 or firstname.lastname@example.org.